Clinical Trial Update: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating BF-200 ALA (Ameluz) with BF-RhodoLED photodynamic therapy for superficial basal cell carcinoma; results have been posted (study status:…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE)
• BF-RhodoLED

Snippet

Sponsor: Biofrontera Inc. | Conditions: Superficial Basal Cell Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-29